Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe?
Objective: To retrospectively investigate the clinicopathological characteristics of ovarian juvenile granulosa cell tumors (JGCTs) and to evaluate the safety of fertility-sparing surgery. Methods: In this study, surgically treated patients with JGCTs diagnosed between January 2004 and October 2018...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2019-01-01
|
| Series: | Reproductive and Developmental Medicine |
| Subjects: | |
| Online Access: | http://www.repdevmed.org/article.asp?issn=2096-2924;year=2019;volume=3;issue=1;spage=24;epage=29;aulast=Guo |
| _version_ | 1811326785769439232 |
|---|---|
| author | Lu Guo Xiao-Cheng Liu Xiu-Ying Chen Xi-Rong Xiao Yu-Qing Qu Bin Li |
| author_facet | Lu Guo Xiao-Cheng Liu Xiu-Ying Chen Xi-Rong Xiao Yu-Qing Qu Bin Li |
| author_sort | Lu Guo |
| collection | DOAJ |
| description | Objective: To retrospectively investigate the clinicopathological characteristics of ovarian juvenile granulosa cell tumors (JGCTs) and to evaluate the safety of fertility-sparing surgery.
Methods: In this study, surgically treated patients with JGCTs diagnosed between January 2004 and October 2018 in our center were identified. Clinicopathological data, survival outcomes, and recurrence rates were examined in these patients.
Results: A total of 8 patients were included. All patients were premenarchal girls or young women (age range, 9–32 years). Irregular vaginal bleeding was the most common presenting symptom. Of them, seven patients were classified with Stage I JGCTs, and they underwent fertility-sparing surgery. One patient who had Stage IIIC JGCT and had completed childbearing underwent complete surgery. Seven patients received adjuvant chemotherapy. The median follow-up duration in the total cohort was 64 months (range, 2–117 months). The overall survival rate in the fertility-sparing group was 100%, whereas the patient with Stage IIIC JGCT died 1 month after the treatment.
Conclusions: Fertility-sparing surgery might not show a negative impact on oncologic outcomes. Fertility sparing could be considered a modified option for patients with Stage I JGCTs. However, due to the limited number of patients, the conclusion must be interpreted with caution, and larger or multicenter studies are needed before conclusions can be drawn. |
| first_indexed | 2024-04-13T14:55:32Z |
| format | Article |
| id | doaj.art-a2f3b0479fd440cf9b798dc1adc5eff3 |
| institution | Directory Open Access Journal |
| issn | 2096-2924 |
| language | English |
| last_indexed | 2024-04-13T14:55:32Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Reproductive and Developmental Medicine |
| spelling | doaj.art-a2f3b0479fd440cf9b798dc1adc5eff32022-12-22T02:42:27ZengWolters Kluwer Health/LWWReproductive and Developmental Medicine2096-29242019-01-0131242910.4103/2096-2924.255993Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe?Lu GuoXiao-Cheng LiuXiu-Ying ChenXi-Rong XiaoYu-Qing QuBin LiObjective: To retrospectively investigate the clinicopathological characteristics of ovarian juvenile granulosa cell tumors (JGCTs) and to evaluate the safety of fertility-sparing surgery. Methods: In this study, surgically treated patients with JGCTs diagnosed between January 2004 and October 2018 in our center were identified. Clinicopathological data, survival outcomes, and recurrence rates were examined in these patients. Results: A total of 8 patients were included. All patients were premenarchal girls or young women (age range, 9–32 years). Irregular vaginal bleeding was the most common presenting symptom. Of them, seven patients were classified with Stage I JGCTs, and they underwent fertility-sparing surgery. One patient who had Stage IIIC JGCT and had completed childbearing underwent complete surgery. Seven patients received adjuvant chemotherapy. The median follow-up duration in the total cohort was 64 months (range, 2–117 months). The overall survival rate in the fertility-sparing group was 100%, whereas the patient with Stage IIIC JGCT died 1 month after the treatment. Conclusions: Fertility-sparing surgery might not show a negative impact on oncologic outcomes. Fertility sparing could be considered a modified option for patients with Stage I JGCTs. However, due to the limited number of patients, the conclusion must be interpreted with caution, and larger or multicenter studies are needed before conclusions can be drawn.http://www.repdevmed.org/article.asp?issn=2096-2924;year=2019;volume=3;issue=1;spage=24;epage=29;aulast=GuoAdjuvant Chemotherapy; Complete Surgery; Fertility-Sparing Surgery; Ovarian Juvenile Granulosa Cell Tumor |
| spellingShingle | Lu Guo Xiao-Cheng Liu Xiu-Ying Chen Xi-Rong Xiao Yu-Qing Qu Bin Li Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe? Reproductive and Developmental Medicine Adjuvant Chemotherapy; Complete Surgery; Fertility-Sparing Surgery; Ovarian Juvenile Granulosa Cell Tumor |
| title | Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe? |
| title_full | Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe? |
| title_fullStr | Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe? |
| title_full_unstemmed | Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe? |
| title_short | Clinicopathological evaluation of ovarian juvenile granulosa cell tumor: Is fertility-sparing surgery safe? |
| title_sort | clinicopathological evaluation of ovarian juvenile granulosa cell tumor is fertility sparing surgery safe |
| topic | Adjuvant Chemotherapy; Complete Surgery; Fertility-Sparing Surgery; Ovarian Juvenile Granulosa Cell Tumor |
| url | http://www.repdevmed.org/article.asp?issn=2096-2924;year=2019;volume=3;issue=1;spage=24;epage=29;aulast=Guo |
| work_keys_str_mv | AT luguo clinicopathologicalevaluationofovarianjuvenilegranulosacelltumorisfertilitysparingsurgerysafe AT xiaochengliu clinicopathologicalevaluationofovarianjuvenilegranulosacelltumorisfertilitysparingsurgerysafe AT xiuyingchen clinicopathologicalevaluationofovarianjuvenilegranulosacelltumorisfertilitysparingsurgerysafe AT xirongxiao clinicopathologicalevaluationofovarianjuvenilegranulosacelltumorisfertilitysparingsurgerysafe AT yuqingqu clinicopathologicalevaluationofovarianjuvenilegranulosacelltumorisfertilitysparingsurgerysafe AT binli clinicopathologicalevaluationofovarianjuvenilegranulosacelltumorisfertilitysparingsurgerysafe |